drugset / Trial / NCT00980603
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
Phase 2
Unknown
144 enrolled
National Cancer Center, Korea
Chungbuk National University Hospital · collabGachon University Gil Medical Center · collabSeoul National University Bundang Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess efficacy and safety of docetaxel alone, docetaxel plus cisplatin, and docetaxel plus S-1 in patients with metastatic gastric cancer after failing 1st line chemotherapy with cisplatin plus S-1 or capecitabine
Timeline
- Start
- 2008-11
- Primary completion
- 2010-11
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 30 mg/m2 | Oral |